Literature DB >> 411419

Comparative pharmacology of amphotericin B and amphotericin B methyl ester in the non-human primate, Macacca mulatta.

F A Jagdis, P D Hoeprich, R M Lawrence, C P Schaffner.   

Abstract

The pharmacokinetics of amphotericin B methyl ester hydrochloride (AME) and commercial deoxycholate-stabilized amphotericin B (AMB) were compared after single doses of 5 mg and 1 mg/kg of body weight, respectively, given intravenously in a period of 3 h to adult female rhesus monkeys (Macaca mulatta). By bioassay, the concentrations of AME were 12.2 to 7.2 times higher in the serum and 7.8 to 2.5 times higher in the urine during the 8 h after infusion. The decline in concentrations of the drugs in sera was consistent with a three-compartment, open pharmacokinetic model; rate constants of transfer of the drugs between the compartments and volumes of distribution were calculated. The overall rate of elimination from the central compartment (the bloodvascular space) was about four times greater for AME than for AMB. Serum urea nitrogen and creatinine concentrations were mildly and transiently increased after infusion of AME, whereas the more severe azotemia that followed infusion of AMB persisted for 5 days. AME was less toxic and achieved a greater urinary outfall than AMB. As the antifungal activity of AME is comparable to that of AMB by testing in vitro, further study is warranted.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 411419      PMCID: PMC429980          DOI: 10.1128/AAC.12.5.582

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  [Hemolytic study of amphotericin B].

Authors:  K AOKAWA; M MATSUSHITA
Journal:  Chiryo       Date:  1962-12-01

2.  COMPARATIVE RESPONSES OF MAMMALIAN ERYTHROCYTES AND MICROBIAL PROTOPLASTS TO POLYENE ANTIBIOTICS AND VITAMIN A.

Authors:  S C KINSKY
Journal:  Arch Biochem Biophys       Date:  1963-08       Impact factor: 4.013

3.  Current status of amphotericin B in the treatment of the systemic fungus infections.

Authors:  V D NEWCOMER; T H STERNBERG; E T WRIGHT; R M REISNER
Journal:  J Chronic Dis       Date:  1959-04

4.  The use of amphotericin B in man.

Authors:  V T ANDRIOLE; H M KRAVETZ
Journal:  JAMA       Date:  1962-04-28       Impact factor: 56.272

5.  Experience with amphotericin B for the treatment of systemic mycoses.

Authors:  J H SEABURY; H E DASCOMB
Journal:  AMA Arch Intern Med       Date:  1958-12

6.  Coccidioidomycosis and its treatment with amphotericin B.

Authors:  M L LITTMAN; P L HOROWITZ; J G SWADEY
Journal:  Am J Med       Date:  1958-04       Impact factor: 4.965

7.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors:  D B LOURIA
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1958-05

8.  Biologically active N-acyl derivatives of polyene macrolide antifungal antibiotics.

Authors:  C P SCHAFFNER; E BOROWSKI
Journal:  Antibiot Chemother (Northfield)       Date:  1961-11

9.  Water-soluble N-acetyl derivatives of heptaene macrolide antifungal antibiotics: microbiological studies.

Authors:  H LECHEVALIER; E BOROWSKI; J O LAMPEN; C P SCHAFFNER
Journal:  Antibiot Chemother (Northfield)       Date:  1961-10

10.  Selective toxicity of the polyene antibiotics and their methyl ester derivatives.

Authors:  W C Chen; I J Sud; D L Chou; D S Feingold
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

View more
  7 in total

1.  Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomolgus monkeys.

Authors:  H Kim; D Loebenberg; A Marco; S Symchowicz; C Lin
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

3.  Therapy of fungal infections.

Authors:  D J Drutz
Journal:  Bull N Y Acad Med       Date:  1982-11

4.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

5.  Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.

Authors:  A C Huston; P D Hoeprich
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats.

Authors:  K R Reuhl; M Vapiwala; M T Ryzlak; C P Schaffner
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

7.  Pharmacokinetics of amphotericin B and flucytosine.

Authors:  A Polak
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.